Información de Innate Pharma SA, dividendo de Innate Pharma SA, actividades de los accionistas y más

Más Datos de Innate Pharma SA Compañía

Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

Información de Innate Pharma SA



Símbolo de cotizaciónIPHA

Nombre de la empresaInnate Pharma SA

Fecha de salida a bolsaOct 31, 2006

Director ejecutivoMr. Jonathan Elliot Dickinson

Número de empleados- -

Tipo de seguridadDepository Receipt

Fin del año fiscalOct 31

Dirección117 avenue de Luminy

CiudadMARSEILLE

Bolsa de valoresNASDAQ Global Select Consolidated

PaísFrance

Código postal13009

Teléfono33430303030

Sitio Webhttps://www.innate-pharma.com/

Símbolo de cotizaciónIPHA

Fecha de salida a bolsaOct 31, 2006

Director ejecutivoMr. Jonathan Elliot Dickinson

Ejecutivos de Innate Pharma SA



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Prof. Eric Vivier, Ph.D.

Senior Vice President, Chief Scientific Officer, Member of the Leadership Team

--

Mr. Nicola Beltraminelli

Vice President, Chief Development Officer, Member of the Leadership Team

--

Mr. Frederic Lombard

Chief Financial Officer, Member of the Leadership Team

--

Mr. Gilles Brisson

Member of the Supervisory Board

--

Mr. Henry Wheeler

Vice President - Investor Relations and Communications, Member of the Leadership Team

--

Ms. Odile Belzunce

Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team

--

Mr. Olivier Martinez

Member of the Supervisory Board, Representative of Bpifrance Participations

--

Ms. Claire De Saint-blanquat

Vice President - Legal and Corporate Affairs, Secretary of the Supervisory Board, Member of the Leadership Team

--

Dr. Sally Bennett

Independent Member of the Supervisory Board

--

Ms. Veronique Chabernaud, M.D.

Independent Member of the Supervisory Board

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Prof. Eric Vivier, Ph.D.

Senior Vice President, Chief Scientific Officer, Member of the Leadership Team

--

Mr. Nicola Beltraminelli

Vice President, Chief Development Officer, Member of the Leadership Team

--

Mr. Frederic Lombard

Chief Financial Officer, Member of the Leadership Team

--

Mr. Gilles Brisson

Member of the Supervisory Board

--

Mr. Henry Wheeler

Vice President - Investor Relations and Communications, Member of the Leadership Team

--

Ms. Odile Belzunce

Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team

--

Desglose de ingresos

Sin datos

Sin datos

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: jue., 16 de oct

Accionistas

Tipos de accionistas

Accionistas

Proporción

AllianceBernstein L.P.

0.07%

Morgan Stanley & Co. International Plc

0.06%

Citadel Advisors LLC

0.03%

Millennium Management LLC

0.01%

Otro

99.84%

Accionistas

Proporción

AllianceBernstein L.P.

0.07%

Morgan Stanley & Co. International Plc

0.06%

Citadel Advisors LLC

0.03%

Millennium Management LLC

0.01%

Otro

99.84%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor/Hedge Fund

0.07%

Research Firm

0.06%

Hedge Fund

0.04%

Otro

99.83%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

19

159.42K

0.17%

-86.66K

2025Q2

17

157.41K

0.17%

-54.22K

2025Q1

22

261.37K

0.29%

-22.81K

2024Q4

23

278.64K

0.34%

-188.16K

2024Q3

25

406.53K

0.50%

-579.77K

2024Q2

27

405.72K

0.50%

-529.94K

2024Q1

29

344.92K

0.22%

-517.69K

2023Q4

32

202.70K

0.25%

-1.13M

2023Q3

36

377.53K

0.47%

-1.02M

2023Q2

36

293.58K

0.36%

-1.21M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

AllianceBernstein L.P.

60.75K

0.07%

+36.48K

+150.33%

Jun 30, 2024

Morgan Stanley & Co. International Plc

51.22K

0.06%

+7.70K

+17.69%

Jun 30, 2025

Citadel Advisors LLC

26.62K

0.03%

+2.35K

+9.68%

Jun 30, 2025

Millennium Management LLC

11.66K

0.01%

-3.67K

-23.91%

Jun 30, 2025

UBS Financial Services, Inc.

5.96K

0.01%

-3.04K

-33.82%

Jun 30, 2025

GAMMA Investing LLC

2.28K

0%

-1.18K

-34.00%

Sep 30, 2025

Rhumbline Advisers Ltd. Partnership

470.00

0%

-205.00

-30.37%

Jun 30, 2025

Barclays Bank PLC

307.00

0%

--

Jun 30, 2025

Optiver Holding B.V.

101.00

0%

--

Jun 30, 2025

Tower Research Capital LLC

--

0%

-3.00

-100.00%

Jun 30, 2025

ETFs relacionados



Actualizado: dom., 2 de nov

Nombre

Proporción

ActivePassive International Equity ETF

0%

DFA Dimensional Intl Sustainability Core 1 ETF

0%

ActivePassive International Equity ETF

Proporción0%

DFA Dimensional Intl Sustainability Core 1 ETF

Proporción0%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos